Published in Gut on September 27, 2005
Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology (2011) 1.85
High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions. Nat Med (2012) 1.44
Host responses to intestinal microbial antigens in gluten-sensitive mice. PLoS One (2009) 1.08
Recent advances in celiac disease. World J Gastroenterol (2011) 1.03
The adaptive immune response in celiac disease. Semin Immunopathol (2012) 0.97
Transglutaminase-2: a new endostatin partner in the extracellular matrix of endothelial cells. Biochem J (2010) 0.94
Mucosal tissue transglutaminase expression in celiac disease. J Cell Mol Med (2008) 0.85
Tissue transglutaminase expression in celiac mucosa: an immunohistochemical study. Virchows Arch (2009) 0.85
Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study. J Clin Immunol (2012) 0.80
Co-occurrence of IgA antibodies against ethanol metabolites and tissue transglutaminase in alcohol consumers: correlation with proinflammatory cytokines and markers of fibrogenesis. Dig Dis Sci (2007) 0.80
Dermatitis herpetiformis: from the genetics to the development of skin lesions. Clin Dev Immunol (2012) 0.80
Igs as Substrates for Transglutaminase 2: Implications for Autoantibody Production in Celiac Disease. J Immunol (2015) 0.78
Deamidation of gliadin peptides in lamina propria: implications for celiac disease. Dig Dis Sci (2008) 0.77
Extracellular matrix proteins and displacement of cultured fibroblasts from duodenal biopsies in celiac patients and controls. J Transl Med (2013) 0.77
The Clinical and Serological Effect of a Gluten-Free Diet in Border Terriers with Epileptoid Cramping Syndrome. J Vet Intern Med (2015) 0.75
Reactive Oxygen Species Affect Transglutaminase Activity and Regulate Hematopoiesis in a Crustacean. J Biol Chem (2016) 0.75
Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology (1992) 10.44
Structural basis for gluten intolerance in celiac sprue. Science (2002) 8.16
Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med (1997) 7.42
Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med (1998) 5.25
Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology (1999) 4.18
The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med (2000) 3.73
Transglutaminases: nature's biological glues. Biochem J (2002) 3.42
Coeliac disease. IV. An investigation into the injurious constituents of wheat in connection with their action on patients with coeliac disease. Acta Paediatr (1953) 3.18
In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med (2000) 3.04
Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology (2002) 2.95
The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology (2002) 2.91
Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol (1998) 2.88
Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med (2002) 2.49
Clinical testing of gliadin fractions in coeliac patients. Clin Sci (Lond) (1984) 1.93
Wheat peptide challenge in coeliac disease. Lancet (1994) 1.88
Glutenin is involved in the gluten-driven mucosal T cell response. Eur J Immunol (1999) 1.68
Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFbeta-dependent matrix deposition. J Cell Sci (2001) 1.61
Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process. J Biol Chem (2002) 1.57
High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: implications for celiac sprue. Biochemistry (2002) 1.49
In vitro (organ culture) studies of the toxicity of specific A-gliadin peptides in celiac disease. Gastroenterology (1988) 1.42
Cell surface localization of tissue transglutaminase is dependent on a fibronectin-binding site in its N-terminal beta-sandwich domain. J Biol Chem (1999) 1.35
Alterations of the intestinal transport and processing of gliadin peptides in celiac disease. Gastroenterology (2003) 1.33
Intestinal T-cell responses to high-molecular-weight glutenins in celiac disease. Gastroenterology (2003) 1.24
Celiac disease: antibody recognition against native and selectively deamidated gliadin peptides. Clin Chem (2001) 1.22
B cell epitopes of gliadin. Clin Exp Immunol (2000) 1.20
Transamidating enzymes. II. A continuous fluorescent method suited for automating measurements of factor XIII in plasma. Anal Biochem (1971) 1.19
Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides. J Biol Chem (2004) 1.15
Expression and enzymatic activity of small intestinal tissue transglutaminase in celiac disease. Am J Gastroenterol (2003) 1.13
Collagens in the liver extracellular matrix bind hepatocyte growth factor. Gastroenterology (1998) 1.10
Coeliac disease: in vivo toxicity of the putative immunodominant epitope. Gut (2003) 1.08
In vivo toxicity of a synthetic dodecapeptide from A gliadin in patients with coeliac disease. Scand J Gastroenterol (1991) 1.08
Transglutaminase-catalyzed cross-linking of fibrils of collagen V/XI in A204 rhabdomyosarcoma cells. Biochemistry (1995) 1.04
Investigation of the putative immunodominant T cell epitopes in coeliac disease. Gut (2003) 0.99
Visualization of purified fibronectin-transglutaminase complexes. J Biol Chem (1992) 0.99
Production of anti-endomysial antibodies in cultured duodenal mucosa: usefulness in coeliac disease diagnosis. Scand J Gastroenterol (2002) 0.99
Autoantibodies of patients with coeliac disease are insufficient to block tissue transglutaminase activity. Gut (2003) 0.94
Interstitial collagens I, III, and VI sequester and modulate the multifunctional cytokine oncostatin M. J Biol Chem (2001) 0.88
Gliadin and tissue transglutaminase complexes in normal and coeliac duodenal mucosa. Clin Exp Immunol (2003) 0.87
Studies in vivo of omega-gliadins in gluten sensitivity (coeliac sprue disease). Clin Sci (Lond) (1998) 0.87
Transglutaminase and coeliac disease: endomysial reactivity and small bowel expression. Clin Exp Immunol (1999) 0.85
Basement membrane and connective tissue proteins in intestinal mucosa of patients with coeliac disease. J Clin Pathol (2002) 0.85
The epithelial mitogen keratinocyte growth factor binds to collagens via the consensus sequence glycine-proline-hydroxyproline. J Biol Chem (2002) 0.84
Spreading and focusing of gluten epitopes in celiac disease. Gastroenterology (2002) 0.81
Characterization of the gliadin-derived peptides which are biologically active in coeliac disease. Clin Chim Acta (1992) 0.77
Determination of anti-omega-gliadin antibodies in serologic tests for coeliac disease. Scand J Gastroenterol (2000) 0.76
Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med (1997) 7.42
Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology (1998) 2.68
Volatile anaesthetics and the atmosphere: atmospheric lifetimes and atmospheric effects of halothane, enflurane, isoflurane, desflurane and sevoflurane. Br J Anaesth (1999) 2.49
In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: evidence for predominant expression in nonparenchymal liver cells. Hepatology (1989) 2.34
The hedgehog pathway regulates remodelling responses to biliary obstruction in rats. Gut (2008) 2.26
Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut (1980) 2.24
Herbal medicine in the treatment of liver diseases. Dig Liver Dis (2007) 2.02
[Results of a S2k-Consensus Conference of the German Society of Gastroenterolgy, Digestive- and Metabolic Diseases (DGVS) in conjunction with the German Coeliac Society (DZG) regarding coeliac disease, wheat allergy and wheat sensitivity]. Z Gastroenterol (2014) 2.02
The production of specific antibodies to native collagens with the chain compositions, (alpha1(I))3, (alpha1(II))3, and (alpha1(I))2alpha 2. J Immunol (1974) 2.02
Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest (1979) 1.87
Differential expression of collagen types I, III, and IV by fat-storing (Ito) cells in vitro. Gastroenterology (1992) 1.78
Specificity of the antibody response in inbred mice to bovine type I and type II collagen. Immunology (1975) 1.77
Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. Gastroenterology (1990) 1.77
Peer discussion on training physicians to be competent communicators: support for a multiple discourse approach. South Med J (1997) 1.73
Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol (1994) 1.64
Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology (1997) 1.64
An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology (2000) 1.60
The integrated value of serum procollagen III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis in the rat. Hepatology (1989) 1.60
H-2-linked genetic control of antibody response to soluble calf skin collagen in mice. Eur J Immunol (1975) 1.56
Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol (1991) 1.55
Energy expenditure of patients with cystic fibrosis. J Pediatr (1987) 1.51
Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol (1997) 1.51
The prognostic significance of first myocardial infarction type (Q wave versus non-Q wave) and Q wave location. The Multicenter Diltiazem Post-Infarction Research Group. J Am Coll Cardiol (1990) 1.48
A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology (1999) 1.40
Significance and incidence of concordance of drug efficacy predictions by Holter monitoring and electrophysiological study in the ESVEM Trial. Electrophysiologic Study Versus Electrocardiographic Monitoring. Circulation (1995) 1.40
[Indications for liver biopsy in liver tumors]. Dtsch Med Wochenschr (2000) 1.38
Characterization of integrin receptors in normal and neoplastic human brain. Am J Pathol (1993) 1.37
Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells. Gastroenterology (1993) 1.35
Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. Am J Pathol (2001) 1.32
Discontinuities in the triple helical sequence Gly-X-Y of basement membrane (type IV) collagen. FEBS Lett (1980) 1.32
Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut (2002) 1.29
Acupuncture and Chinese herbal medicine in the treatment of patients with seasonal allergic rhinitis: a randomized-controlled clinical trial. Allergy (2004) 1.28
Chemical, pharmacological and clinical profile of the East Asian medical plant Centella asiatica. Phytomedicine (2000) 1.27
Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology (1992) 1.27
A prospective comparative study of five measures of gluten-free diet adherence in adults with coeliac disease. Aliment Pharmacol Ther (2007) 1.24
Covalent structure of mouse type-IV collagen. Isolation, order and partial amino-acid sequence of cyanogen-bromide and tryptic peptides of pepsin fragment P1 from the alpha 1(IV) chain. Eur J Biochem (1982) 1.21
Cellular localization of type I III and IV procollagen gene transcripts in normal and fibrotic human liver. Am J Pathol (1990) 1.19
Cellular localization of procollagen gene transcripts in inflammatory bowel diseases. Gastroenterology (1992) 1.17
Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. J Am Coll Cardiol (1993) 1.17
Effects of elevated CO2 on grain yield and quality of wheat: results from a 3-year free-air CO2 enrichment experiment. Plant Biol (Stuttg) (2009) 1.15
Suppression of T cell-mediated injury in human gut by interleukin 10: role of matrix metalloproteinases. Gastroenterology (1998) 1.14
Soluble collagen VI drives serum-starved fibroblasts through S phase and prevents apoptosis via down-regulation of Bax. J Biol Chem (1999) 1.14
Temporal and spatial patterns of transin/stromelysin RNA expression following toxic injury in rat liver. Virchows Arch B Cell Pathol Incl Mol Pathol (1991) 1.14
Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol (2001) 1.14
Ultrastructural localization of extracellular matrix proteins in liver biopsies using ultracryomicrotomy and immuno-gold labelling. Histopathology (1990) 1.13
Disulphide bonds in wheat gluten: cystine peptides derived from gluten proteins following peptic and thermolytic digestion. Z Lebensm Unters Forsch (1995) 1.13
Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer (2002) 1.12
Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut (2000) 1.11
Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol (1999) 1.10
Ito cell heterogeneity: desmin-negative Ito cells in normal rat liver. Hepatology (1994) 1.09
Coeliac disease: in vivo toxicity of the putative immunodominant epitope. Gut (2003) 1.08
TGFbeta1 in liver fibrosis: time to change paradigms? FEBS Lett (2001) 1.08
Immunohistochemical investigation of collagen subtypes in human glioblastomas. Virchows Arch A Pathol Anat Histopathol (1988) 1.08
Immunohistochemical distribution of collagens types IV, V, and VI and of pro-collagens types I and III in human alveolar bone and dentine. J Histochem Cytochem (1986) 1.07
The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem Biophys Res Commun (1995) 1.07
Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis (2009) 1.07
Using cross-cultural input to adapt the Functional Assessment of Chronic Illness Therapy (FACIT) scales. Acta Oncol (1999) 1.07
Analysis and clinical effects of gluten in coeliac disease. Eur J Gastroenterol Hepatol (2001) 1.06
Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Br J Cancer (2003) 1.05
Involvement of more than a single polypeptide chain in the helical antigenic determinants of collagen. Eur J Immunol (1973) 1.05
Development of the emergency physician job satisfaction measurement instrument. Am J Emerg Med (1994) 1.05
Cocarcinogenic effects of alcohol in hepatocarcinogenesis. Gut (2002) 1.04
Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol (1999) 1.03
Kupffer cell-derived 95-kd type IV collagenase/gelatinase B: characterization and expression in cultured cells. Hepatology (1995) 1.03
Collagen VI regulates normal and transformed mesenchymal cell proliferation in vitro. Exp Cell Res (1996) 1.02
Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut (2005) 1.02
Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J Biol Chem (2000) 1.01
Vimentin expression of newly formed rat bile duct epithelial cells in secondary biliary fibrosis. Virchows Arch A Pathol Anat Histopathol (1989) 1.01
Coeliac activity of the gliadin peptides CT-1 and CT-2. Z Lebensm Unters Forsch (1986) 1.00
Avenin fails to induce a Th1 response in coeliac tissue following in vitro culture. Gut (2003) 0.99
The leukocyte integrin Mac-1 (CD11b/CD18) contributes to binding of human granulocytes to collagen. Exp Cell Res (1995) 0.99
Investigation of the putative immunodominant T cell epitopes in coeliac disease. Gut (2003) 0.99
Visualization of type I and II collagens in tissue sections by immunohistologic techniques. J Immunol (1976) 0.99
Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver (2001) 0.99
Structure of mouse type IV collagen. Amino-acid sequence of the C-terminal 511-residue-long triple-helical segment of the alpha 2(IV) chain and its comparison with the alpha 1(IV) chain. Eur J Biochem (1986) 0.98
c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res (1993) 0.97
[Infections caused by Yersinia enterocolitica: bacteriological, serological, epidemiological and immunological findings in 51 cases (author's transl)]. Dtsch Med Wochenschr (1979) 0.97
Odontogenic myxoma--characterisation of the extracellular matrix (ECM) of the tumour stroma. Eur J Cancer B Oral Oncol (1994) 0.97
Cellular localization of laminin gene transcripts in normal and fibrotic human liver. Am J Pathol (1989) 0.96
A chondroitin/dermatan sulfate form of CD44 is a receptor for collagen XIV (undulin). Exp Cell Res (1996) 0.96
Disulphide bonds in wheat gluten: further cystine peptides from high molecular weight (HMW) and low molecular weight (LMW) subunits of glutenin and from gamma-gliadins. Z Lebensm Unters Forsch (1993) 0.96
Acetaldehyde regulates the gene expression of matrix-metalloproteinase-1 and -2 in human fat-storing cells. Life Sci (1994) 0.95
Human myofibroblastlike cells obtained by outgrowth are representative of the fibrogenic cells in the liver. Hepatology (1995) 0.95
All-trans and 9-cis retinoic acid alter rat hepatic stellate cell phenotype differentially. Gut (1999) 0.95
Acute hepatitis induced by Greater Celandine (Chelidonium majus). Scand J Gastroenterol (2003) 0.95
Soluble collagen VI induces tyrosine phosphorylation of paxillin and focal adhesion kinase and activates the MAP kinase erk2 in fibroblasts. Exp Cell Res (1999) 0.95
The cultivable human oral gluten-degrading microbiome and its potential implications in coeliac disease and gluten sensitivity. Clin Microbiol Infect (2013) 0.95
Increased prevalence of Helicobacter pylori infection in patients with celiac disease. Am J Gastroenterol (2000) 0.95
Fibrogenesis and fibrolysis in collagenous colitis. Patterns of procollagen types I and IV, matrix-metalloproteinase-1 and -13, and TIMP-1 gene expression. Am J Pathol (1999) 0.94
Autoantibodies of patients with coeliac disease are insufficient to block tissue transglutaminase activity. Gut (2003) 0.94
Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats. Hepatology (2001) 0.94
Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor. J Physiol Pharmacol (2000) 0.94
Differential regulation of extracellular matrix synthesis during liver regeneration after partial hepatectomy in rats. Hepatology (1999) 0.94
Interaction between psychiatric and autoimmune disorders in coeliac disease patients in the Northeastern United States. Aliment Pharmacol Ther (2009) 0.93
Effect of salbutamol on resting energy expenditure in patients with cystic fibrosis. J Pediatr (1987) 0.93